Display options
Share it on

Iran J Basic Med Sci. 2015 Jun;18(6):623-6.

Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance.

Iranian journal of basic medical sciences

Abdollah Ardebili, Abdolaziz Rastegar Lari, Maryam Beheshti, Elnaz Rastegar Lari

Affiliations

  1. Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
  2. Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  3. Department of Microbiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  4. Department of Science and Environment, Faculty of Science, Technology and Communication, Luxembourg University and Faculty of Science and Environment University of Liege, Liege, Belgium.

PMID: 26221488 PMCID: PMC4509960

Abstract

OBJECTIVES: We investigated the contribution of gyrA and parC mutational mechanism in decreased ciprofloxacin susceptibility of Acinetobacter baumannii isolated from burn wound infections.

MATERIALS AND METHODS: Ciprofloxacin susceptibility of 50 A. baumannii isolates was evaluated by disk diffusion and agar dilution methods. PCR and sequencing were performed for detection of mutation in gyrA and parC genes.

RESULTS: The 44 and 4 isolates of A. baumannii exhibited full and intermediate-resistant to ciprofloxacin, respectively. Overall, the 42 isolates with double mutations of gyrA and parC genes showed a higher level of ciprofloxacin resistance than the 3 isolates with single mutations of gyrA or parC.

CONCLUSION: Simultaneous mutations in gyrA and parC genes are expected to play a major role in high-level fluoroquinolone resistance in A. baumannii; albeit a single mutation in DNA topoisomerase IV could occasionally be associated with intermediate-resistance to these antimicrobials.

Keywords: Acinetobacter baumannii; Burn; Ciprofloxacin resistance; gyrA; parC

References

  1. Microbiol Immunol. 2005;49(7):647-53 - PubMed
  2. Clin Microbiol Infect. 2008 Feb;14(2):161-7 - PubMed
  3. Ann Lab Med. 2014 Nov;34(6):433-8 - PubMed
  4. Microb Biotechnol. 2009 Jan;2(1):40-61 - PubMed
  5. Antimicrob Agents Chemother. 1995 May;39(5):1201-3 - PubMed
  6. Indian J Pathol Microbiol. 2010 Apr-Jun;53(2):290-3 - PubMed
  7. J Clin Microbiol. 2008 Aug;46(8):2499-507 - PubMed
  8. Curr Opin Investig Drugs. 2009 Feb;10(2):150-6 - PubMed
  9. Infection. 1990 Jul-Aug;18(4):234-6 - PubMed
  10. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S120-6 - PubMed
  11. Osong Public Health Res Perspect. 2011 Dec;2(3):164-70 - PubMed
  12. Jundishapur J Microbiol. 2014 Jan;7(1):e8691 - PubMed
  13. J Clin Microbiol. 2006 Aug;44(8):2974-6 - PubMed
  14. Indian J Med Microbiol. 2004 Apr-Jun;22(2):97-103 - PubMed
  15. Clin Infect Dis. 2009 Jan 1;48(1):1-12 - PubMed

Publication Types